Sara Freeman

News

Geriatric Assessment Predicts Overall Survival in AML

Author:: Sara Freeman

Publish date: November 11, 2011

Major Finding: Scores of less than 9 out of 12 on the Short Physical Performance Battery (SPPB) and less than 77 out of 100 on a Modified Mini-Men...

News

MRI Tool Helps to Predict Conversion to Pediatric MS

Author:: Sara Freeman

Publish date: November 8, 2011

Major Finding: The presence of one or more T1-weighted hypointense lesions and one or more T2-weighted periventricular lesions significantly incre...

News

Study Finds Signs of Progression to Clinically Definite MS

Author:: Sara Freeman

Publish date: November 4, 2011

Major Finding: The independent predictors of clinically definite MS in patients who had not received disease-modifying treatment, included having ...

News

MRI Predicts Response After Starting MS Treatment

Author:: Sara Freeman

Publish date: November 4, 2011

Major Finding: The presence of more than two GdE T1-weighted lesions at 1 year was associated with nearly sixfold greater odds for nonresponse to ...

News

Study: Liraglutide Helps Nondiabetics Keep the Weight Off

Author:: Sara Freeman

Publish date: November 3, 2011

Major Finding: Body weight was decreased by 6.11% in the liraglutide-treated individuals but by just 0.05% in those given placebo (P less than .00...

News

MS Trials Show Complexity of Targeting B Cells

Author:: Sara Freeman

Publish date: November 2, 2011

News

MS Activity Returns Soon After Stopping Natalizumab

Author:: Sara Freeman

Publish date: November 1, 2011

Major Finding: The estimated percentage of patients who had a clinical relapse or MRI scan meeting rescue criteria was 61% for placebo, 60% for gl...

News

Weekly Exenatide Similar to Daily Liraglutide

Author:: Sara Freeman

Publish date: November 1, 2011

News

Daclizumab Shows Promise in Multiple Sclerosis Trial

Author:: Sara Freeman

Publish date: October 31, 2011

Major Finding: The annualized relapse rate at 1 year was 0.21 for 150 mg daclizumab and 0.23 for 300 mg, compared with 0.46 for placebo (P less th...

News

Laquinimod Halted MS Disability But Not Relapses

Author:: Sara Freeman

Publish date: October 31, 2011

Major Finding: The 2-year annualized relapse rate was not significantly different between laquinimod and placebo (0.28 vs. 0.34, respectively), bu...

News

Laquinimod Halted MS Disability But Not Relapses

Author:: Sara Freeman

Publish date: October 31, 2011

Major Finding: The 2-year annualized relapse rate was not significantly different between laquinimod and placebo (0.28 vs. 0.34, respectively), bu...

News

Alemtuzumab Bests Interferon for Preventing MS Relapse

Author:: Sara Freeman

Publish date: October 27, 2011

Major Finding: At 2 years, 78% of 376 patients treated with alemtuzumab and 59% of 187 treated with IFNB-1a remained relapse free (P less than .00...

News

Possible Cancer Link to Diabetes Drugs Stirs Controversy

Author:: Sara Freeman

Publish date: October 27, 2011

Major Finding: The risk of pancreatic cancer was increased with exenatide and sitagliptin versus control treatments, with respective odds ratios o...

News

Dimethyl Fumarate Halved MS Relapse Rate

Author:: Sara Freeman

Publish date: October 26, 2011

Major Finding: The cumulative probability of relapse with 240 mg dimethyl fumarate at 2 years was 27% when given twice daily and 26% when given th...

News

Conventional LFTs Often Miss Liver Disease in Type 2 Diabetes

Author:: Sara Freeman

Publish date: October 5, 2011

Major Finding: The positive predictive values of ALT and GGT above normal in predicting fibrosis were low, at 26% and 29%, respectively.